A pooled primate screen finds that MYD88-CD40 boosts CAR-T
suppressor cells 9 ) and are critical in the mode of action of approved drugs (eg, NK cells in the context of anti-CD38 monoclonal antibodies 10 ).Finally, to define the methods and create userfriendly tools for standardized and routine assessment of immune age in routine practice.The authors should be commended for taking the first step in such a relevant patient population!Conflict-of-interest disclosure: B.P.
Authors
- Mark B. Leick (ORCID: https://orcid.org/0000-0003-3111-0221)
Institutions
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Blood
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1182/blood.2025030745
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Celgene